Xeglyze® (abametapir) Lotion, 0.74%

About Pelthos Therapeutics

Pelthos Therapeutics is a San Diego-based biopharmaceutical company with a mission to commercialize innovative therapies for patients with unmet dermatological needs. Its core achievement is the FDA approval of ZELSUVMI™ for molluscum contagiosum, complemented by a strategic portfolio of acquired, late-stage topical products. The company's strategy leverages a dual approach: a commercial engine for launching acquired assets and a proprietary NITRICIL™ nitric oxide platform for future internal development, aiming to build a sustainable, revenue-generating dermatology franchise.

Therapeutic Areas